Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

Manon Allaire 1, 2, * Pierre Nahon 3 Richard Layese 4 Valérie Bourcier 5 Carole Cagnot 6 Patrick Marcellin 7 Dominique Guyader 8 Stanislas Pol 9, 10, 11 Dominique Larrey 12, 13 Victor de Ledinghen 14 Denis Ouzan 15 Fabien Zoulim 16 Dominique Roulot 17 Albert Tran 18 Jean-Pierre Bronowicki 19 Jean-Pierre Zarski 20, 21 Ghassan Riachi 22 P. Calès 23 Jean-Marie Péron 24, 25 Laurent Alric 26 Marc Bourlière 27 Philippe Mathurin 28 Jean-Frédéric Blanc 29, 30 Armand Abergel 31, 32, 33, 34, 35 Lawrence Serfaty 36 Ariane Mallat 37, 38, 39 Jean-Didier Grangé 40 Pierre Attali 41 Yannick Bacq 42 Claire Wartelle Thong Dao 1 Dominique Thabut 43 Christophe Pilette Christine Silvain 44 Christos Christidis 45 Eric Nguyen-Khac 46 Brigitte Bernard-Chabert 47 David Zucman 48 Vincent Di Martino 49 Angela Sutton 5 Eric Letouzé 3 Etienne Audureau 50, 4 Françoise Roudot-Thoraval 50
* Auteur correspondant
Abstract : Data on extrahepatic cancers (EHCs) in compensated viral cirrhosis are limited. The objective of the prospective multicenter Agence Nationale de Recherche sur le SIDA et les Hépatites virales CO12 CirVir cohort was to assess the occurrence of all clinical events in patients with compensated viral cirrhosis, including all types of cancer. Patients with the following inclusion criteria were enrolled in 35 French centers: (1) biopsy-proven hepatitis B virus (HBV) or hepatitis C virus (HCV) cirrhosis, (2) Child-Pugh A, or (3) absence of previous liver complications including primary liver cancer (PLC). Patients were followed up prospectively every 6 months. The standardized mortality ratio (SMR) was calculated according to age and gender using 5-year periods. The impact of sustained viral response (SVR) in HCV patients and maintained viral suppression in HBV patients were assessed using time-dependent analysis. A total of 1,671 patients were enrolled between 2006 and 2012 (median age, 54.9 years; men, 67.3%; HCV, 1,323; HBV, 317; HCV-HBV, 31). Metabolic features and excessive alcohol and tobacco consumption were recorded in 15.2%, 36.4%, and 56.4% of cases, respectively. After a median follow-up of 59.7 months, 227 PLCs were diagnosed (5-year cumulative incidence [CumI] 13.4%) and 93 patients developed EHC (14 patients with lymphoid or related tissue cancer and 79 with solid tissue cancer; 5-year EHC CumI, 5.9%). Compared to the general French population, patients were younger at cancer diagnosis, with significantly higher risk of EHC in HCV patients (SMR, 1.31; 95 confidence interval [CI], 1.04-1.64; P = 0.017) and after SVR (SMR = 1.57; 95% CI, 1.08-2.22; P = 0.013). EHC was the fourth leading cause of death in the whole cohort and the first in patients with viral control/eradication.

CONCLUSION: Compared to the general French population, HCV cirrhosis is associated with a higher risk of EHC and the first cause of death in patients with viral cirrhosis who achieve virological control/eradication. (Hepatology 2018).

Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Okina Université d'Angers <>
Soumis le : vendredi 29 mai 2020 - 09:36:09
Dernière modification le : jeudi 9 septembre 2021 - 11:29:52



Manon Allaire, Pierre Nahon, Richard Layese, Valérie Bourcier, Carole Cagnot, et al.. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Hepatology, Wiley-Blackwell, 2018, 68 (4), pp.1245-1259. ⟨10.1002/hep.30034⟩. ⟨hal-02648452⟩



Consultations de la notice